...
Project Scope |
This Project team will create a White Paper with recommendations for |
...
Treatment Emergent Definitions, with a focus on Phase 2-4 clinical trials. |
...
This White Paper will build upon a White Paper that outlines results from a survey on current practices, indicating variation that can likely be reduced. |
...
Recommendations will |
...
be based on the desired end-in-mind, and may or may not be consistent with current practices. |
| Project Leads |
|---|
...
Mary Nilsson - nilsson_mary_e@lilly.com
...
| Emails | |
|---|---|
William Palo, Abbvie | |
Nicola Newton, PHUSE Project Assistant |
| ||||||
|---|---|---|---|---|---|---|
|
Objectives & Deliverables | Timelines |
|---|---|
White Paper - Recommended Definition of Treatment-Emergent Adverse Events in Clinical Trials' | Q3 2024 |